Titre:
  • A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Auteur:Hamilton, Andrew; Larsimont, Denis; Paridaens, R.; Drijkoningen, M; Van de Vijver, Marc J; Bruning, Peter; Hanby, A; Houston, S; Treilleux, I; Guastalla, Jean Paul; Van Vreckem, A; Sylvester, R.; Piccart-Gebhart, Martine
Informations sur la publication:Clinical breast cancer, 1, 3, page (233-40; discussion 241-2)
Statut de publication:Publié, 2000-10
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Agents, Phytogenic -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- metabolism
Breast Neoplasms -- pathology
Doxorubicin -- therapeutic use
Female
Forecasting
Humans
Immunoenzyme Techniques
Middle Aged
Paclitaxel -- therapeutic use
Prognosis
Prospective Studies
Proto-Oncogene Proteins c-bcl-2 -- metabolism
Receptor, erbB-2 -- metabolism
Tumor Suppressor Protein p53 -- metabolism
Note générale:Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:1526-8209
info:pmid/11899648